Of the patients who underwent CAR T infusion, at the time of treatment, 15.4% had MYC and BCL-2 and/or BCL-6 rearrangements, consistent with double-hit/triple-hit lymphoma, 3.8% had an Eastern Cooperative Oncology Group (ECOG) performance score of from 2 to 3, 25.6% had bulky disease, 66.7% had extranodal disease, 41.7% had an elevated LDH, and 10.3% had an IPI of ≥3. Here, BCL6 is linked to lymphoma.